Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1605786A induction study in moderate-to-severe Crohn's disease
NL-OMON39870Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vercirnon in Crohn's disease (2 arms), sponsored by GSK. Primary endpoint: Clinical response at Week 12. Started Jul 2013; status: active, not recruiting.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON39870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39870.